and in vivo, in a process termed seeding [15, 20] . Thus, it appears plausible that exogenous Aβ seeds could induce pathology in human subjects. However, it has been reported that the cellular prion protein, PrP C , can bind different Aβ species, especially oligomers [3, 14] . Furthermore, conflicting reports have suggested that infectious prions (PrP Sc ) can exacerbate Aβ deposition at a time point where plaques are already present, with both pathologies working synergistically, but also that misfolded Aβ can actually interfere with prion pathogenesis [16, 18, 19] . Given these findings, it is important to consider that PrP Sc inoculations could influence Aβ pathology, but the role of PrP Sc in initiating cerebral β-amyloidosis is still unclear. To this end, we inoculated APP transgenic mice on a PrP C wild-type or heterozygous knockout background with infectious PrP Sc prions to investigate whether PrP Sc alters the onset of Aβ pathology. APP23 mice expressing human amyloid precursor protein (APP) with a Swedish mutation (KM670/671NL) were intracerebrally inoculated (hippocampus, bregma: 2.5 mm posterior; ± 2.0 mm lateral; 1.8 mm ventral) with infectious RMLPrP Sc or wild-type (WT) brain extracts (1% w/v) prepared from RML-PrP Sc infected or healthy CD1 mice, respectively, using the Precellys system (5500 rpm, 2 × 20 s, Bertin Instruments) (Fig. 1a , Supplemental Methods). All PrP Sc -inoculated mice developed terminal prion disease and were sacrificed after 176 days post injection (median). Histological analysis with Hematoxylin & Eosin and SAF84 (PrP Sc , 1:250) revealed that brains displayed typical vacuolation (spongiosis) and PrPimmunoreactive deposits in sick animals, which was not detectable in WT-injected animals of the same age (Fig. 1a) . Using an in-house pan-Aβ antibody (CN6, 1:1000) (Supplemental Methods), no induced Aβ pathology was detected in the hippocampus of PrP Sc prion-injected animals, while conversely, the injection of minimal Aβ seeds and a similar incubation period does yield Aβ deposition as demonstrated previously [20] .
Given that the incubation period of the suggested transmission of human Aβ pathology is 10-40 years for both transmission via contaminated dura grafts and growth hormone [2, 4, ), which is known to increase the prion incubation period until terminal sickness [1, 6] . Indeed, APP23-PrP +/− mice injected with PrP Sc prions survived an extra 69 days after intrahippocampal inoculation as described above (median survival: 245 days post injection) before being sacrificed due to prion disease with the expected PrP Sc -positive staining using SAF84 (Fig. 1b) . Nevertheless, none of the animals injected with PrP Sc prions presented with detectable seeded Aβ deposition after staining sections for Aβ (CN6) (Fig. 1b) . In parallel, APP23-PrP +/− mice were also inoculated with brain extracts prepared from aged APP23 Aβ-laden brains homogenized with the Precellys system as above (10% w/v) followed by a 3000 g centrifugation (5 min). All Aβ-injected animals showed obvious induced Aβ pathology as expected [15, 20] (Fig. 1b) .
The potential of Aβ pathology transmission under specific circumstances in humans is interesting both from a basic biology and human health perspective [2, 4, 7, 8, [10] [11] [12] [13] 17] . However, given that these human studies are observational, there are questions on the mechanism behind the increased Aβ deposition. We have found that intrahippocampal inoculations of infectious RML prions into APP23 transgenic mice caused prion disease but did not induce Aβ pathology in the hippocampus after long incubation periods that are sufficient to detect seeded Aβ pathology caused by nanomolar amounts of Aβ (one seeding unit) [20] . This argues against a direct cross-seeding effect of PrP Sc prions on Aβ or an indirect effect of prion disease leading to Aβ pathology. This conclusion is supported by the recent report that patients who received growth hormone treatments but did not have prion disease still contained significant Aβ pathology and other instances suggesting Aβ pathology in prion disease patients is an age-related phenomenon [9, 17] .
It is worth noting that although PrP Sc did not induce Aβ pathology before terminal prion disease, these inoculations were intracerebral and were meant to provide a model system for dura mater grafting or for contaminated surgical instruments. Instances of Aβ pathology after peripheral growth hormone treatment in humans with iCJD could be caused by Aβ seeds in the growth hormone extract traveling to the brain similar to studies in APP transgenic mice [2, 4, 5, 11, 17] . However, it cannot be excluded that a peripheral prion infection indirectly influences Aβ pathology [18] , and thus mechanistically would contrast intracerebral exposure. It is also important to consider that a different PrP Sc prion strain may harbor Aβ pathology inducing activity.
From our work, we can conclude that misfolded Aβ introduced during treatment may be responsible for induction of Aβ pathology in these human cases as opposed to being the by-product of iCJD prion infection. Future work will need to determine whether cases of Aβ pathology transmission could eventually develop into clinical Alzheimer's disease.
